Publications by authors named "S V Zaichick"
Rise in Calcium (Ca) and hyperactive Ca-dependent phosphatase calcineurin represent two key determinants of a-synuclein (a-syn) pathobiology implicated in Parkinson's Disease (PD) and other neurodegenerative diseases. Calcineurin activity can be inhibited with FK506, a Food and Drug Administration (FDA)-approved compound. Our previous work demonstrated a protective effect of low doses of FK506 against a-syn pathology in various models of a-syn related pathobiology.
View Article and Find Full Text PDFOctopamine is a well-established invertebrate neurotransmitter involved in fight or flight responses. In mammals, its function was replaced by epinephrine. Nevertheless, it is present at trace amounts and can modulate the release of monoamine neurotransmitters by a yet unidentified mechanism.
View Article and Find Full Text PDFNeurotropic alphaherpesviruses initiate infection in exposed mucosal tissues and, unlike most viruses, spread rapidly to sensory and autonomic nerves where life-long latency is established. Recurrent infections arise sporadically from the peripheral nervous system throughout the life of the host, and invasion of the central nervous system may occur, with severe outcomes. These viruses directly recruit cellular motors for transport along microtubules in nerve axons, but how the motors are manipulated to deliver the virus to neuronal nuclei is not understood.
View Article and Find Full Text PDFArticle Synopsis
- Ykt6 is a SNARE protein that plays a crucial role in vesicular fusion, transitioning between active and inactive forms in different cellular compartments.
- Research showed that Ykt6 is phosphorylated at a specific site influenced by calcium signaling, which triggers a change in its shape from a closed to an open form.
- This open form alters Ykt6's interactions with other proteins, which can disrupt secretory and autophagy pathways, potentially increasing toxicity in models of Parkinson's disease.
Objective: The aim of this study was to clarify the differences between the prostatic levels of chemical elements in patients with benign prostatic hyperplasia (BPH) and healthy male.
Methods: We evaluated the prostatic level of 66 chemical elements in 43 patients with BPH and 37 healthy males. Measurements were performed using five instrumental analytical methods.